Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model.
Respiratory syncytial virus (RSV) is widely recognized as a leading cause of pneumonia, with substantial mortality, in bone marrow transplant recipients. We tested the efficacy of a systemic monoclonal antibody (MAB) preparation possessing a high titer of anti-RSV neutralizing antibody, palivizumab (Synagis) for prophylaxis and therapy of RSV infection in cytoxan (CY) immunosuppressed cotton rats, a model in which the efficacy of a polyclonal anti-RSV product (Respigam) has been demonstrated. Both prophylaxis and therapy with this MAB were highly effective in reducing pulmonary viral replication. However, multiple sequential therapeutic doses of MAB were necessary to control rebound viral replication in continually suppressed animals.
Ottolini
M G
MG
Department of Pediatrics, F Edward Hébert School of Medicine, The Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4799, USA.
Curtis
S R
SR
Mathews
A
A
Ottolini
S R
SR
Prince
G A
GA
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D016867:Immunocompromised Host; D023421:Models, Animal; D000069455:Palivizumab; D051381:Rats; D011919:Rats, Inbred Strains; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy* / Q000276:immunology* / Q000517:prevention & control; D012136:Respiratory Syncytial Viruses / Q000187:drug effects / Q000254:growth & development; D033581:Stem Cell Transplantation / Q000009:adverse effects; D016896:Treatment Outcome; D014779:Virus Replication / Q000187:drug effects
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab